TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 55.01% | -53.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 135.17% | -57.66% | |||
| Operating Income | -135.17% | 57.66% | |||
| Income Before Tax | -154.85% | 55.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -154.85% | 55.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -154.85% | 55.28% | |||
| EBIT | -135.17% | 57.66% | |||
| EBITDA | -136.44% | 57.70% | |||
| EPS Basic | -85.92% | 78.53% | |||
| Normalized Basic EPS | -85.94% | 78.53% | |||
| EPS Diluted | -85.92% | 78.53% | |||
| Normalized Diluted EPS | -85.94% | 78.53% | |||
| Average Basic Shares Outstanding | 37.08% | 108.24% | |||
| Average Diluted Shares Outstanding | 37.08% | 108.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||